Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184

Gynecologic Oncology

Volumn 119, Issue 3, 2010, Pages 538-542

  Cella, David ^a   Huang, Helen ^b   Homesley, Howard D ^c   Montag, Anthony ^d   Salani, Ritu ^e   De Geest, Koen ^f   Lee, Roger ^g   Spirtos, Nick M ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g Tacoma General Hospital   (United States)

^h Women's Cancer Center   (United States)

Author keywords

Endometrial cancer; Neuropathy; Neurotoxicity; Peripheral neuropathy; Quality of life

Indexed keywords

CISPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; PATIENT ATTITUDE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SELF REPORT; SENSORY NEUROPATHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; SELF REPORT;

EID: 78149360166     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.022     Document Type: Article

References (13)

1. S. Gibbons, A. Martinez, M. Schray, K. Podratz, R. Stanhope, and G. Garton Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma Int J Radiat Oncol Biol Phys 21 1991 1019 1025
2. G. Sutton, J.H. Axelrod, B.N. Bundy, T. Roy, H.D. Homesley, and J.H. Malfetano Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group study Gynecol Oncol 97 2005 755 763
3. J.T. Thigpen, M.F. Brady, H.D. Homesley, J. Malfetano, B. DuBeshter, and R.A. Burger Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 2004 3902 3908
4. M.E. Randall, V.L. Filiaci, H. Muss, N.M. Spirtos, R.S. Mannel, and J. Fowler Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 24 2006 36 44
5. D.W. Bruner, A. Barsevick, C. Tian, M. Randall, R. Mannel, and D.E. Cohn Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study Quality of Life Research 16 2006 89 100
6. S. Lincoln, J.A. Blessing, R.B. Lee, and T.F. Rocereto Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 88 2003 277 281
7. H.D. Homesley, V.L. Filiaci, S.K. Gibbons, H.J. Long, D. Cella, and N.M. Spirtos A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study Gynecol Oncol 112 2009 543 552
8. E. Calhoun, E. Welshman, C.H. Chang, J.R. Lurain, D.A. Fishman, and T.L. Hunt Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systematic chemotherapy Int J Gynecol Cancer 13 2003 741 748
9. H. Huang, M. Brady, D. Cella, and G. Fleming Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel induced neurologic symptoms: a Gynecologic Oncology Group (GOG) study Int J Gynecol Cancer 17 2007 387 393
10. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G.C. Reid, and A.R. Munkarah Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 2004 2159 2166
11. J.A. Kopec, S.R. Land, R.S. Cecchini, P.A. Ganz, D. Cella, and J.P. Costantino Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin J Supportive Oncol 4 2006 W1 W8
12. S. Land, J.A. Kopec, R. Cecchini, P. Ganz, S. Wieand, and L. Colangelo Neurotoxicity with oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP protocol C-07 J Clin Oncol. 25 2007 2205 2211
13. D. Moore, J. Donnelly, W. McGuire, L. Almadrones, D.F. Cella, and T.J. Herzog Limited access trial using amifostine for protection against cisplatin and three-hour paclitaxel-included neurotoxicity: a phase II study of the Gynecologic Oncology Group J Clin Oncol 21 2003 4207 4213